Maze Therapeutics, Inc. (MAZE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 20M | 0 | 0 | 0 | 0 | 0 | 2.5M | 165M | 0 |
| Revenue Growth % | - | - | -100% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 444K | 499K | 0 | 649K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 2.22% | - | - | - | - | - | - | - | - |
| Gross Profit | 19.56M | -499K | 0 | -649K | 0 | 0 | 2.5M | 165M | 0 |
| Gross Margin % | 97.78% | - | - | - | - | - | 100% | 100% | - |
| Gross Profit Growth % | - | - | -100% | -100.39% | - | - | - | - | - |
| Operating Expenses | 46.11M | 37.56M | 32.97M | 35.83M | 35.4M | 29.73M | 26.73M | 25.45M | 23.05M |
| OpEx % of Revenue | 230.54% | - | - | - | - | - | 1069.16% | 15.42% | - |
| Selling, General & Admin | 12.4M | 10.49M | 7.78M | 8.37M | 7.82M | 7.51M | 6.87M | 5.9M | 7.01M |
| SG&A % of Revenue | 62.02% | - | - | - | - | - | 274.88% | 3.58% | - |
| Research & Development | 33.7M | 27.57M | 25.19M | 28.11M | 27.58M | 22.22M | 19.86M | 19.55M | 16.05M |
| R&D % of Revenue | 168.52% | - | - | - | - | - | 794.28% | 11.85% | - |
| Other Operating Expenses | 0 | -499K | 0 | -649K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.55M | -38.06M | -32.97M | -36.47M | -35.4M | -29.73M | -24.23M | 139.56M | -23.05M |
| Operating Margin % | -132.76% | - | - | - | - | - | -969.16% | 84.58% | - |
| Operating Income Growth % | 24.99% | -28.03% | -36.06% | -126.14% | - | -28.96% | - | - | - |
| EBITDA | -26.11M | -37.56M | -32.39M | -35.83M | -34.72M | -29.02M | -23.44M | 140.41M | -22.07M |
| EBITDA Margin % | -130.54% | - | - | - | - | - | -937.64% | 85.1% | - |
| EBITDA Growth % | 24.79% | -29.42% | -38.19% | -125.51% | - | -31.47% | - | - | - |
| D&A (Non-Cash Add-back) | 444K | 499K | 571K | 649K | 684K | 705K | 788K | 854K | 976K |
| EBIT | -26.55M | -38.06M | -30.09M | -33.68M | -35.4M | -29.73M | -24.23M | 139.56M | -23.05M |
| Net Interest Income | -866K | 3.49M | 2.88M | 2.79M | 2.62M | 1.52M | 1.85M | 1.01M | 304K |
| Interest Income | 0 | 3.49M | 2.88M | 2.79M | 2.62M | 1.52M | 1.85M | 1.01M | 304K |
| Interest Expense | 866K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.35M | 3.49M | 2.88M | 2.79M | 2.62M | -128K | -802K | 1.23M | -3.53M |
| Pretax Income | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M | -29.85M | -25.03M | 140.78M | -26.58M |
| Pretax Margin % | -121.04% | - | - | - | - | - | -1001.24% | 85.32% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -275K | -279K | 1.73M | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.92% | 1.11% | 1.23% | 0% |
| Net Income | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M | -26.58M |
| Net Margin % | -121.04% | - | - | - | - | - | -990.08% | 84.28% | - |
| Net Income Growth % | 26.16% | -16.87% | -21.55% | -124.22% | - | -11.3% | - | - | - |
| Net Income (Continuing) | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M | -29.58M | -24.75M | 139.06M | -26.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.45 | -0.87 | -0.66 | -0.77 | -0.75 | -0.11 | -0.06 | 0.98 | -0.61 |
| EPS Growth % | 39.89% | -676.79% | -1091.34% | -178.57% | - | 81.55% | - | - | - |
| EPS (Basic) | -0.45 | -0.87 | -0.66 | -0.77 | -0.75 | -0.11 | -0.06 | 0.98 | -0.61 |
| Diluted Shares Outstanding | 53.9M | 42.98M | 45.78M | 43.85M | 43.8M | 43.8M | 43.78M | 43.79M | 43.78M |
| Basic Shares Outstanding | 53.9M | 42.98M | 45.78M | 43.85M | 43.8M | 43.8M | 43.78M | 43.79M | 43.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |